We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Soleno Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 220 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 225 → 0 (-225)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $2.08B → $0 (-$2.08B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 220

120.6% less ownership

Funds ownership: 120.6% → 0% (-121%)

Holders
–
Holders Change
-225
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
220
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$194M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$148M
3
BlackRock
BlackRock
New York
-$125M
4
State Street
State Street
Massachusetts
-$89.8M
5
ACA
Avoro Capital Advisors
New York
-$77M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
51
Trexquant Investment
Connecticut
– -$7.43M -221,928 Closed
Marshall Wace
52
Marshall Wace
United Kingdom
– -$7.41M -221,214 Closed
Alyeska Investment Group
53
Alyeska Investment Group
Illinois
– -$7.28M -217,500 Closed
SFM
54
Sphera Funds Management
Israel
– -$7.24M -216,281 Closed
RHJA
55
Rice Hall James & Associates
California
– -$6.9M -206,147 Closed
Hudson Bay Capital Management
56
Hudson Bay Capital Management
Connecticut
– -$6.81M -203,291 Closed
EMFAT
57
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$6.72M -200,727 Closed
ABG
58
Ally Bridge Group
New York
– -$6.7M -200,000 Closed
BCM
59
Boxer Capital Management
California
– -$6.7M -200,000 Closed
NPT
60
National Philanthropic Trust
Pennsylvania
– -$6.7M -200,000 Closed
SAM
61
SEB Asset Management
– -$6.28M -187,475 Closed
Squarepoint
62
Squarepoint
New York
– -$6.21M -185,337 Closed
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
– -$6.2M -185,317 Closed
BCA
64
Buckley Capital Advisors
Florida
– -$6.08M -181,750 Closed
HSBC Holdings
65
HSBC Holdings
United Kingdom
– -$5.83M -174,204 Closed
HS
66
HighVista Strategies
Massachusetts
– -$5.53M -165,227 Closed
NB
67
Nicolet Bankshares
Wisconsin
– -$5.25M -156,766 Closed
Deutsche Bank
68
Deutsche Bank
Germany
– -$4.97M -148,374 Closed
BHCM
69
Brevan Howard Capital Management
Jersey
– -$4.54M -135,621 Closed
NFT
70
Nan Fung Trinity
Hong Kong
– -$4.22M -126,050 Closed
BFM
71
Boothbay Fund Management
New York
– -$4.17M -124,519 Closed
SFCM
72
Seven Fleet Capital Management
California
– -$3.88M -115,770 Closed
GIM
73
Granahan Investment Management
Massachusetts
– -$3.84M -114,825 Closed
Nuveen
74
Nuveen
North Carolina
– -$3.51M -104,738 Closed
TAM
75
TFG Asset Management
Cayman Islands
– -$3.42M -102,125 Closed
1 2
3
4 5

SLNO Hedge Fund Activity: Q2 2026 in Review

0 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2026, worth a combined $0 — down 100% from $2.08B a quarter earlier.

Sellers outnumbered buyers: 220 funds closed out of SLNO and 0 opened new positions — a net loss of 220 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Fidelity Investments, exiting entirely with an estimated $194M sold.

  • 0 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2026, down from 225 in Q1 2026.
  • Funds reported $0 of Soleno Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics positions in Q2 2026 and 220 closed out, a net change of -220 holders.
  • The largest Soleno Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $194M sold.

Based on aggregated 13F filings for Q2 2026.